Human rhinovirus type 16: mutant V1210A requires capsid-binding drug for assembly of pentamers to form virions during morphogenesis.
Our laboratory has previously reported isolation of human rhinovirus type 16 (HRV16) mutants which depend on WIN 52035 to grow. A rapid rise of progeny virus infectivity occurred when drug was added late in growth cycles, suggesting that the drug-dependence lesion was at the step of virus assembly (W. Wang et al., J. Virol. 72:1210-1218, 1998). Here, we report that capsid subunits, 5S protomers and 14S pentamers, of a drug-dependent mutant were produced normally in the absence of drug, but mutant 80S empty capsids and 150S provirions were not formed, maturation cleavage of provirions (VP0 --> VP2 + VP4) did not occur, and the unassembled mutant capsid subunits were degraded with a half-life of 15 min. Drug was not required by mutant virus for attachment, uncoating, RNA synthesis and protein synthesis, and polyprotein processing except maturation cleavage. The requirement of drug for assembly of mutant pentamers to form provirions and the rapid assembly of preformed subunits (synthesized in the absence of drug) after drug addition suggested that after native pentamers (P5) have been formed they must be converted to an assembly active state (P5(*)), possibly by a conformational change induced by the binding of drug. We propose that pocket factor plays the same role in wild-type virus. In addition, we also report the construction and the properties of a full-length cDNA clone of HRV16, pR16.11, which produces in vitro transcripts with infectivity similar to that of virion RNA. This cDNA clone is available at the American Type Culture Collection.
Lee
Wai-Ming
WM
Institute for Molecular Virology, University of Wisconsin, Madison 53706, USA. wlee5@facstaff.wisc.edu
Wang
Wensheng
W
D002213:Capsid / Q000378:metabolism*; D018076:DNA, Complementary / Q000235:genetics / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D007555:Isoxazoles / Q000378:metabolism* / Q000494:pharmacology; D009154:Mutation; D020815:Polyproteins / Q000378:metabolism; D012367:RNA, Viral / Q000096:biosynthesis; D012229:Rhinovirus / Q000145:classification / Q000235:genetics / Q000378:metabolism / Q000472:pathogenicity*; D014764:Viral Proteins / Q000378:metabolism; D014771:Virion / Q000737:chemistry* / Q000378:metabolism; D019065:Virus Assembly / Q000187:drug effects*; D014779:Virus Replication
D018076:DNA, Complementary; D007555:Isoxazoles; D020815:Polyproteins; D012367:RNA, Viral; D014764:Viral Proteins; C059730:Win 52035